US President Donald Trump praised Prime Minister Narendra Modi for efforts to curb illicit opium cultivation in India, even as the country remained on the US list of major drug transit or illicit drug-producing nations. The designation, outlined in a Presidential Determination submitted to Congress, highlights geographic, commercial, and economic factors that allow illicit drugs or precursor chemicals to move through a country’s territory. The document explicitly states that inclusion on the list does not necessarily reflect a country’s current counterdrug efforts or level of cooperation with Washington.

The list includes 23 countries, among them Afghanistan, China, and Pakistan, with India designated for its role in the global drug supply chain. Trump emphasized continued cooperation under the US-India Drug Policy Framework, noting the two nations established a Drug Policy Executive Working Group to address illicit narcotics trafficking, precursor chemicals, and pharmaceutical supply chain security. The designation comes amid Washington’s focus on disrupting international drug supply chains, including the movement of precursor chemicals used to manufacture synthetic drugs.

Trump highlighted what he described as "historic progress" by his administration in tackling drug trafficking and narcoterrorist organizations. He cited tighter border security, lower drug seizures, and a decline in overdose deaths as evidence of this progress. According to the White House’s 2026 National Drug Control Strategy, stronger bilateral counterdrug cooperation with countries like India is a priority. Trump also called on China to take stronger action against the flow of precursor chemicals used to manufacture fentanyl, methamphetamine, and other synthetic drugs, noting that Beijing remains the world’s largest producer of such chemicals.

The US has made disrupting precursor-chemical supply chains a central part of its broader counter-drug strategy, which emphasizes international cooperation to prevent legitimate trade channels from being exploited for illicit drug production. Trump stated he had raised the issue directly with Chinese President Xi Jinping and noted that Beijing introduced licensing requirements last year for companies exporting designated precursor chemicals to North America.

The designation of India as a major drug transit country has drawn attention to the country’s role in the global drug trade, despite its efforts to curb illicit opium cultivation. The US document clarifies that the designation is based on a combination of factors rather than a judgment on the effectiveness of India’s counterdrug efforts. While the government has implemented measures to reduce opium poppy cultivation, the country remains a key transit point for precursor chemicals used in the production of synthetic drugs.

The situation remains unclear regarding the extent of India’s current counterdrug efforts and how they compare to the US’s expectations. The designation does not imply a failure to combat the drug trade, but it does underscore the challenges in ensuring that legitimate trade channels are not exploited for illicit purposes. As the US continues to focus on international cooperation to disrupt drug supply chains, the role of countries like India and China will remain central to its strategy. Further details on the effectiveness of India’s measures and the impact of the designation on bilateral relations are yet to be fully assessed.